Skip to main content
. 2023 Dec 26;13(1):53. doi: 10.3390/cells13010053

Figure 2.

Figure 2

RNA-Seq profiling showing the first two principal components of wild-type and G2019S-LRRK2 microglia after zymosan and MLi-2 stimulation. We used the first two principal components, PC1 and PC2, of all samples in the study. Data are from two independent experiments. Treatments with zymosan and MLi-2 and genotype (wild-type and G2019S-LRRK2). Note that samples are separated largely by treatment, and to a lesser extent by genotype.